Linzagolix choline, identified by the CAS number 1321816-57-2, is a chemical compound primarily studied for its potential therapeutic applications, particularly in the treatment of conditions such as uterine fibroids and endometriosis. It functions as a selective progesterone receptor modulator (SPRM), which means it can bind to progesterone receptors and influence their activity, thereby modulating hormonal effects in the body. This compound is characterized by its ability to reduce estrogen levels and inhibit the growth of hormone-sensitive tissues. Linzagolix choline is typically administered in oral form and has been the subject of various clinical trials to evaluate its efficacy and safety profile. Its pharmacokinetics, including absorption, distribution, metabolism, and excretion, are crucial for understanding its therapeutic potential and side effects. As with many pharmaceutical compounds, the specific characteristics, including solubility, stability, and interaction with other drugs, are essential for its development and clinical use.

Linzagolix choline

1321816-57-2: Linzagolix choline, identified by the CAS number 1321816-57-2, is a chemical compound primarily studied for its potential therapeutic applications, particularly in the treatment of conditions such as uterine fibroids and endometriosis. It functions as a selective progesterone receptor modulator (SPRM), which means it can bind to progesterone receptors and influence their activity, thereby modulating hormonal effects in the body. This compound is characterized by its ability to reduce estrogen levels and inhibit the growth of hormone-sensitive tissues. Linzagolix choline is typically administered in oral form and has been the subject of various clinical trials to evaluate its efficacy and safety profile. Its pharmacokinetics, including absorption, distribution, metabolism, and excretion, are crucial for understanding its therapeutic potential and side effects. As with many pharmaceutical compounds, the specific characteristics, including solubility, stability, and interaction with other drugs, are essential for its development and clinical use.

Linzagolix choline is a GnRH antagonist. It can be used to study pain associated with uterine fibroids and endometriosis.

CAS 1321816-57-2

Linzagolix choline

Linzagolix choline

Ref: 54-BUP03285

Linzagolix choline

Ref: TM-T25742

Linzagolix Choline

Ref: 4Z-L-232002